(DNLI) Denali Therapeutics - Ratings and Ratios
RIPK1 Inhibitor, LRRK2 Inhibitor, EIF2B Activator, TV Enzyme Replacement, Antibody TV
DNLI EPS (Earnings per Share)
DNLI Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 60.8% |
| Value at Risk 5%th | 90.1% |
| Relative Tail Risk | -9.91% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.58 |
| Alpha | -59.61 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.493 |
| Beta | 1.413 |
| Beta Downside | 1.449 |
| Drawdowns 3y | |
|---|---|
| Max DD | 65.20% |
| Mean DD | 34.26% |
| Median DD | 34.91% |
Description: DNLI Denali Therapeutics November 11, 2025
Denali Therapeutics Inc. (NASDAQ: DNLI) is a U.S.-based biopharmaceutical company that discovers and develops disease-modifying therapies for neurodegenerative disorders and lysosomal storage diseases.
Its pipeline spans several modality platforms: a RIPK1 inhibitor (Eclitasertib/SAR443122) for peripheral inflammatory conditions; an eIF2B activator (DNL343) targeting ALS; an LRRK2 inhibitor (BIIB122/DNL151) for Parkinson’s disease; a granulin-targeting antibody-drug conjugate (TAK-594/DNL593) for frontotemporal dementia; enzyme-replacement candidates for MPS III A (DNL126) and MPS II (Tividenofusp alfa/DNL310); and Transport Vehicle (TV) programs such as DNL952 for Pompe disease, DNL111 for Parkinson’s/Gaucher, and DNL622 for Hurler syndrome. The company also pursues OTV (oligonucleotide-transport vehicle) approaches against tau (DNL628) and α-synuclein (DNL422), plus an antibody-TV directed at Aβ (DNL921) for Alzheimer’s disease.
Recent data (Q3 2024) show DNLI holding approximately $1.2 billion in cash and marketable securities, with a cash-burn rate of roughly $150 million per quarter, reflecting heavy R&D spend (≈ $300 million YoY). The biotech sector is being driven by an aging global population, increasing prevalence of neurodegenerative disease, and a surge in venture capital funding that has lifted average biotech valuations by ~ 30 % year-over-year.
For a deeper, data-rich assessment of DNLI’s valuation and risk profile, you may find the analyst tools on ValueRay worth exploring.
DNLI Stock Overview
| Market Cap in USD | 2,380m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2017-12-08 |
| Return 12m vs S&P 500 | -46.5% |
| Analyst Rating | 4.79 of 5 |
DNLI Dividends
Currently no dividends paidDNLI Growth Ratios
| CAGR 3y | -16.68% |
| CAGR/Max DD Calmar Ratio | -0.26 |
| CAGR/Mean DD Pain Ratio | -0.49 |
| Current Volume | 1281.1k |
| Average Volume | 1421.7k |
Piotroski VR‑10 (Strict, 0-10) 0.0
| error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM) |
| FCFTA -0.32 (>2.0%) and ΔFCFTA -4.79pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.30 (>3.0%) and CFO -349.6m > Net Income -479.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 10.27 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (171.4m) change vs 12m ago 1.55% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.0% (prev 22.00%; Δ -22.00pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -11.94 (EBITDA TTM -511.6m / Interest Expense TTM -43.8m) >= 6 (WARN >= 3) |
Altman Z'' -16.44
| (A) 0.72 = (Total Current Assets 934.7m - Total Current Liabilities 91.1m) / Total Assets 1.17b |
| (B) -1.54 = Retained Earnings (Balance) -1.80b / Total Assets 1.17b |
| warn (B) unusual magnitude: -1.54 — check mapping/units |
| (C) -0.39 = EBIT TTM -522.7m / Avg Total Assets 1.33b |
| (D) -12.88 = Book Value of Equity -1.79b / Total Liabilities 139.2m |
| Total Rating: -16.44 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 26.28
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -24.08% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.05 = 2.50 |
| 5. Debt/Ebitda 0.19 = 2.47 |
| 6. ROIC - WACC (= -56.39)% = -12.50 |
| 7. RoE -40.79% = -2.50 |
| 8. Rev. Trend -43.79% = -3.28 |
| 9. EPS Trend -8.23% = -0.41 |
What is the price of DNLI shares?
Over the past week, the price has changed by +16.11%, over one month by +14.66%, over three months by +20.61% and over the past year by -38.70%.
Is Denali Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DNLI is around 14.09 USD . This means that DNLI is currently overvalued and has a potential downside of -19.21%.
Is DNLI a buy, sell or hold?
- Strong Buy: 15
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the DNLI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 31.6 | 81.2% |
| Analysts Target Price | 31.6 | 81.2% |
| ValueRay Target Price | 16.2 | -7.2% |
DNLI Fundamental Data Overview November 02, 2025
P/S = 3643.6484
P/B = 2.1639
Beta = 1.294
Revenue TTM = 0.0 USD
EBIT TTM = -522.7m USD
EBITDA TTM = -511.6m USD
Long Term Debt = 46.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 8.87m USD (from shortTermDebt, last quarter)
Debt = 46.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -94.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.53b USD (2.38b + Debt 46.6m - CCE 899.0m)
Interest Coverage Ratio = -11.94 (Ebit TTM -522.7m / Interest Expense TTM -43.8m)
FCF Yield = -24.08% (FCF TTM -368.0m / Enterprise Value 1.53b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 3.04m) / Revenue TTM)
Tobins Q-Ratio = 1.31 (Enterprise Value 1.53b / Total Assets 1.17b)
Interest Expense / Debt = 45.28% (Interest Expense 21.1m / Debt 46.6m)
Taxrate = -0.02% (negative due to tax credits) (68.0k / -422.7m)
NOPAT = -522.8m (EBIT -522.7m * (1 - -0.02%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 10.27 (Total Current Assets 934.7m / Total Current Liabilities 91.1m)
Debt / Equity = 0.05 (Debt 46.6m / totalStockholderEquity, last quarter 1.03b)
Debt / EBITDA = 0.19 (negative EBITDA) (Net Debt -94.6m / EBITDA -511.6m)
Debt / FCF = 0.26 (negative FCF - burning cash) (Net Debt -94.6m / FCF TTM -368.0m)
Total Stockholder Equity = 1.17b (last 4 quarters mean from totalStockholderEquity)
RoA = -41.08% (Net Income -479.0m / Total Assets 1.17b)
RoE = -40.79% (Net Income TTM -479.0m / Total Stockholder Equity 1.17b)
RoCE = -42.81% (EBIT -522.7m / Capital Employed (Equity 1.17b + L.T.Debt 46.6m))
RoIC = -44.51% (negative operating profit) (NOPAT -522.8m / Invested Capital 1.17b)
WACC = 11.87% (E(2.38b)/V(2.43b) * Re(11.22%) + D(46.6m)/V(2.43b) * Rd(45.28%) * (1-Tc(-0.00)))
Discount Rate = 11.22% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 14.09%
Fair Price DCF = unknown (Cash Flow -368.0m)
EPS Correlation: -8.23 | EPS CAGR: 80.68% | SUE: 4.0 | # QB: 1
Revenue Correlation: -43.79 | Revenue CAGR: -0.42% | SUE: -0.01 | # QB: 0
Additional Sources for DNLI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle